Can-Fite's Phase II Lowe syndrome trial is under review in Italy
CANF•Italian health authorities are reviewing Can-Fite's proposed Phase II trial of piclidenoson for Lowe syndrome, which would assess five adults receiving oral treatment twice daily for six months.
1. Trial proposal under review
Italian health authorities are reviewing Can-Fite's proposed Phase II trial of piclidenoson for Lowe syndrome. The trial would evaluate efficacy and safety in five adults receiving oral treatment twice daily for six months.
